Amifostine (hydrate) (Synonyms: Ethyol, WR 2721) |
| Catalog No.GC42785 |
La amifostina (hidrato) (WR2721 trihidrato) es un agente citoprotector de amplio espectro y un radioprotector. La amifostina (hidrato) protege selectivamente los tejidos normales del daÑo causado por la radiaciÓn y la quimioterapia. La amifostina (hidrato) es un potente factor inducible por hipoxia-α1 (HIF-α1) e inductor de p53. La amifostina (hidrato) protege las células del daÑo al eliminar los radicales libres derivados del oxÍgeno. La amifostina (hidrato) reduce la toxicidad renal y tiene acciÓn antiangiogénica.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 112901-68-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Amifostine is a prodrug that through dephosphorylation by alkaline phosphatase is converted to an active thiol, WR 1065 that has free radical scavenging, DNA protective, and hypoxia inducing activities. Because of the differential expression of alkaline phosphatase in normal versus neoplastic tissues, the cytoprotection conferred by amifostine is selective, enabling as much as 100-fold greater accumulation of WR 1065 in normal tissues than in tumor cells. Amifostine has been used to reduce toxicity in normal tissues exposed to radiation or chemotherapeutic agents. In mouse fibroblasts and various cancer cells, amifostine (IC50 = 4 mM) has been shown to activate p53 protein, to induce the expression of the cyclin-dependent kinase inhibitor p21, and to arrest cells at the G1/S transition through a p53-dependent mechanism.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *